🔴 NNVC is trading 11.2% down today as traders reassess rally following FDA rare pediatric designation

NNVC is trading 11.2% down at $1.22 in pre-market, pulling back after a sharp recent advance following news that the FDA granted Rare Pediatric Disease Drug designation for NV-387.

• The designation for NV-387 as a measles treatment potentially qualifies NanoViricides for a priority review voucher, which can be valued at up to $100 million.
• Market participants appear to be reassessing the stock's valuation and the implications of the earlier rally.